Research Analysts Set Expectations for CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities researchers at Brookline Capital Management lifted their FY2025 EPS estimates for Caribou Biosciences in a research report issued on Wednesday, November 12th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of ($1.27) per share for the year, up from their prior forecast of ($1.42). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q4 2025 earnings at ($0.32) EPS, FY2027 earnings at ($1.44) EPS, FY2028 earnings at ($1.97) EPS and FY2029 earnings at ($3.67) EPS.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.The company had revenue of $2.20 million for the quarter, compared to analyst estimates of $1.94 million.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Caribou Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 24th. HC Wainwright upped their price target on shares of Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Truist Financial set a $7.00 price objective on shares of Caribou Biosciences in a research report on Tuesday, November 4th. Finally, Citigroup lifted their price objective on shares of Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Caribou Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Caribou Biosciences Stock Down 5.0%

Shares of NASDAQ CRBU opened at $1.89 on Monday. The business has a 50-day moving average price of $2.24 and a 200 day moving average price of $1.76. The stock has a market cap of $176.66 million, a PE ratio of -1.11 and a beta of 2.59. Caribou Biosciences has a 52-week low of $0.66 and a 52-week high of $3.54.

Hedge Funds Weigh In On Caribou Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Next Capital Management LLC purchased a new position in Caribou Biosciences during the 2nd quarter worth $25,000. Creative Planning purchased a new stake in shares of Caribou Biosciences in the second quarter valued at about $25,000. R Squared Ltd acquired a new position in shares of Caribou Biosciences during the third quarter worth about $29,000. Hudson Bay Capital Management LP purchased a new position in Caribou Biosciences during the second quarter worth about $30,000. Finally, Savant Capital LLC purchased a new position in Caribou Biosciences during the second quarter worth about $36,000. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.